Abatacept leads to significant improvements in all American college of rheumatology core components in patients with an inadequate response to anti-TNF therapy in the attain trial Annual European Congress of Rheumatology Schiff, M., Dougados, M., Luggen, M., Espinoza, L., Nuamah, I., Aranda, R., Becker, J., Genovese, M. BMJ PUBLISHING GROUP. 2005: 435–436

View details for Web of Science ID 000229909102105